NewAmsterdam Pharma's Upcoming Conferences
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a biopharmaceutical leader, is set to engage in critical medical and investor conferences in November. The company aims to showcase its advancements in the treatment of cardiovascular disease (CVD) through its groundbreaking developments in oral, non-statin medications designed for patients with elevated low-density lipoprotein cholesterol (LDL-C).
AHA Scientific Sessions Presentations
During the 2024 American Heart Association (AHA) Scientific Sessions, NewAmsterdam will present important safety and efficacy data from the pivotal Phase 3 BROOKLYN study. This study focuses on evaluating obicetrapib, a novel treatment for patients with Heterozygous Familial Hypercholesterolemia. The presentation is scheduled for November 18, where Stephen Nicholls, M.B.B.S., Ph.D., will share insights into the outcomes from this vital research.
Significance of Obicetrapib
Obicetrapib represents a promising advancement in treating patients at risk of cardiovascular ailments. As an oral, low-dose CETP inhibitor, it has demonstrated statistically significant LDL-lowering effects in previous trials. The positive side effect profile observed in various studies adds to its appeal, making it a vital player in the fight against CVD.
Jefferies London Healthcare Conference
NewAmsterdam will also participate in the Jefferies London Healthcare Conference from November 19-21. In a dedicated fireside chat on November 21, key executives including Michael Davidson, M.D., the CEO, and Chief Scientific Officer John Kastelein, M.D., will discuss the company’s strategies and successes, providing further insights into its innovative treatments.
Ongoing Research and Trials
The company is not only focused on the ongoing trials, but it is also conducting new pivotal investigations to enhance its therapeutic offerings. The BROADWAY trial, designed to assess obicetrapib as a monotherapy, and the TANDEM trial, which studies obicetrapib in combination therapy with ezetimibe, are crucial to expanding access to effective lipid-lowering therapies.
A Comprehensive Approach to Cardiovascular Health
Completed enrollment in significant trials like PREVAIL highlights the company’s commitment to understanding the broader impact of cardiovascular therapies. This trial, with over 9,500 enrolled patients, aims to ascertain how obicetrapib may contribute to reducing major adverse cardiovascular events.
Commercial Partnerships
NewAmsterdam has entered into a commercial partnership granting exclusive rights for obicetrapib in Europe to the Menarini Group. This partnership is a strategic move aimed at maximizing the potential of obicetrapib across various treatment landscapes in the cardiovascular domain.
The Vision of NewAmsterdam Pharma
The mission at NewAmsterdam Pharma focuses on enhancing patient care, particularly in areas where existing treatment options fall short. Their dedication to creating safe and effective LDL-lowering therapies underscores the company's vision of addressing significant unmet medical needs.
Contact Information
For further inquiries, stakeholders can reach out to Matthew Philippe at NewAmsterdam Pharma or explore the company's website for investor-related information. NewAmsterdam is committed to keeping both the medical community and investors informed through their various platforms.
Frequently Asked Questions
What is NewAmsterdam Pharma's core focus?
NewAmsterdam focuses on developing oral, non-statin medications for cardiovascular disease treatment, specifically targeting patients with elevated LDL-C.
What key data will be presented at the AHA Conference?
The company will present safety and efficacy data from their Phase 3 BROOKLYN study on obicetrapib for Heterozygous Familial Hypercholesterolemia.
Who will be presenting at the Jefferies London Healthcare Conference?
Michael Davidson, M.D., John Kastelein, M.D., and Ian Somaiya will represent the company during the conference discussions.
What trials is NewAmsterdam currently conducting?
NewAmsterdam is conducting multiple pivotal trials including BROADWAY and TANDEM, assessing obicetrapib as monotherapy and combination therapies.
What is the significance of the partnership with Menarini Group?
This partnership allows NewAmsterdam to expand market access for obicetrapib in Europe, optimizing treatment opportunities for cardiovascular conditions.
